UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 42

Sortiert nach

Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway–mediated diseases

Blood, 2011-10, Vol.118 (17), p.4705-4713

2011

Volltextzugriff (PDF)

Telomerase Contributes to Tumorigenesis by a Telomere Length-Independent Mechanism

Proceedings of the National Academy of Sciences - PNAS, 2002-10, Vol.99 (20), p.12606-12611

2002

Volltextzugriff (PDF)

Immortalization and transformation of primary human airway epithelial cells by gene transfer

Oncogene, 2002-07, Vol.21 (29), p.4577-4586

2002

Volltextzugriff (PDF)

Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus

Blood, 2018-04, Vol.131 (17), p.1960-1973

2018

Volltextzugriff (PDF)

CRISPR-Cas Gene Editing to Cure Serious Diseases: Treat the Patient, Not the Germ Line

American journal of bioethics, 2015-12, Vol.15 (12), p.38-40

2015

Volltextzugriff (PDF)

Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia

Journal of clinical oncology, 2015-04, Vol.33 (11), p.1252-1257

2015

Volltextzugriff (PDF)

The human complement receptor type 2 (CR2)/CR1 fusion protein TT32, a novel targeted inhibitor of the classical and alternative pathway C3 convertases, prevents arthritis in active immunization and passive transfer mouse models

Molecular immunology, 2019-01, Vol.105, p.150-164

2019

Volltextzugriff (PDF)

Functional Inactivation of the Retinoblastoma Protein Requires Sequential Modification by at Least Two Distinct Cyclin-cdk Complexes

Molecular and Cellular Biology, 1998-02, Vol.18 (2), p.753-761

1998

Volltextzugriff (PDF)

Creation of human tumour cells with defined genetic elements

Nature (London), 1999-07, Vol.400 (6743), p.464-468

1999

Volltextzugriff (PDF)

Amonafide: a potential role in treating acute myeloid leukemia

Expert opinion on investigational drugs, 2011-07, Vol.20 (7), p.995-1003

2011

Volltextzugriff (PDF)

Genes involved in senescence and immortalization

Current Opinion in Cell Biology, 2000-12, Vol.12 (6), p.705-709

2000

Volltextzugriff (PDF)

Interstitial lung disease following erlotinib (Tarceva®) in a patient who previously tolerated gefitinib (Iressa®)

Journal of oncology pharmacy practice, 2005-09, Vol.11 (3), p.127-130

2005

Volltextzugriff (PDF)

Serum Response Factor Is Required for Immediate-Early Gene Activation yet Is Dispensable for Proliferation of Embryonic Stem Cells

Molecular and Cellular Biology, 2001-04, Vol.21 (8), p.2933-2943

2001

Volltextzugriff (PDF)

Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia

Leukemia research, 2010-04, Vol.34 (4), p.487-491

2010

Volltextzugriff (PDF)

Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human b-globin locus

Blood, 2018-04, Vol.131 (17), p.1960-1973

2018

Volltextzugriff (PDF)

Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate

Biopharmaceutics & drug disposition, 2010-01, Vol.31 (1), p.72-81

2010

Volltextzugriff (PDF)

Crispr/Cas9- Mediated Genome Editing of Human CD34+ Cells Upregulate Fetal Hemoglobin to Clinically Relevant Levels in Single Cell-Derived Erythroid Colonies

Blood, 2016-12, Vol.128 (22), p.3623-3623

2016

Volltextzugriff (PDF)

Induction of Fetal Hemoglobin Synthesis By Crispr/Cas9-Mediated Disruption of the β-Globin Locus Architecture

Blood, 2016-12, Vol.128 (22), p.321-321

2016

Volltextzugriff (PDF)

Complement Activation in Patients with Acquired Thrombotic Thrombocytopenic Pupura (TTP)

Blood, 2012-11, Vol.120 (21), p.3323-3323

2012

Volltextzugriff (PDF)

Safety and Pharmacokinetics of the Complement Inhibitor TT30 in a Phase I Trial for Untreated PNH Patients

Blood, 2015-12, Vol.126 (23), p.2137-2137

2015

Volltextzugriff (PDF)

Re-Creating Hereditary Persistence of Fetal Hemoglobin (HPFH) to Treat Sickle Cell Disease (SCD) and β-Thalassemia

Blood, 2016-12, Vol.128 (22), p.4708-4708

2016

Volltextzugriff (PDF)

Mortality From Thrombotic Thrombocytopenic Purpura Is Related to Complement Hyperactivation

Blood, 2012-11, Vol.120 (21), p.488-488

2012

Volltextzugriff (PDF)

Regulation of cyclin E transcription by E2Fs and retinoblastoma protein

Oncogene, 1996-03, Vol.12 (6), p.1173-1180

1996

Volltextzugriff (PDF)

TT30, a Novel Human Complement Inhibitor in Development for Paroxysmal Nocturnal Hemoglobinuria and Other Hemolytic Disorders, Demonstrates Red Blood Cell Surface Targeting and Retention In a Model of Complement Alternative Pathway-Mediated Hemolysis

Blood, 2010-11, Vol.116 (21), p.638-638

2010

Volltextzugriff (PDF)

Amonafide L-Malate (AS1413) in Combination with Cytarabine Is Equally Effective in Older and Younger Patients with Secondary Acute Myeloid Leukemia (AML); Final Data From a Phase II Study

Blood, 2009-11, Vol.114 (22), p.1047-1047

2009

Volltextzugriff (PDF)

1 – 25 von 42

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(37)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(22)
Life Sciences & Biomedicine
(21)
Humans
(20)
Male
(8)
Animals
(7)
Female
(6)
Adult
(5)
Biochemistry & Molecular Biology
(5)
Cell Biology
(5)
Mice
(5)
Oncology
(5)
Biological And Medical Sciences
(4)
Dna-Binding Proteins
(4)
Middle Aged
(4)
Cell Division
(3)
Cells
(3)
Cells, Cultured
(3)
Hematology
(3)
Leukemia, Myeloid, Acute - Drug Therapy
(3)
Medical Sciences
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway–mediated diseases

Telomerase Contributes to Tumorigenesis by a Telomere Length-Independent Mechanism

Immortalization and transformation of primary human airway epithelial cells by gene transfer

Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus

CRISPR-Cas Gene Editing to Cure Serious Diseases: Treat the Patient, Not the Germ Line

Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia

The human complement receptor type 2 (CR2)/CR1 fusion protein TT32, a novel targeted inhibitor of the classical and alternative pathway C3 convertases, prevents arthritis in active immunization and passive transfer mouse models

Functional Inactivation of the Retinoblastoma Protein Requires Sequential Modification by at Least Two Distinct Cyclin-cdk Complexes

Creation of human tumour cells with defined genetic elements

Amonafide: a potential role in treating acute myeloid leukemia

Genes involved in senescence and immortalization

Interstitial lung disease following erlotinib (Tarceva®) in a patient who previously tolerated gefitinib (Iressa®)

Serum Response Factor Is Required for Immediate-Early Gene Activation yet Is Dispensable for Proliferation of Embryonic Stem Cells

Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia

Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human b-globin locus

Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate

Crispr/Cas9- Mediated Genome Editing of Human CD34+ Cells Upregulate Fetal Hemoglobin to Clinically Relevant Levels in Single Cell-Derived Erythroid Colonies

Induction of Fetal Hemoglobin Synthesis By Crispr/Cas9-Mediated Disruption of the β-Globin Locus Architecture

Complement Activation in Patients with Acquired Thrombotic Thrombocytopenic Pupura (TTP)

Safety and Pharmacokinetics of the Complement Inhibitor TT30 in a Phase I Trial for Untreated PNH Patients

Re-Creating Hereditary Persistence of Fetal Hemoglobin (HPFH) to Treat Sickle Cell Disease (SCD) and β-Thalassemia

Mortality From Thrombotic Thrombocytopenic Purpura Is Related to Complement Hyperactivation

Regulation of cyclin E transcription by E2Fs and retinoblastoma protein

TT30, a Novel Human Complement Inhibitor in Development for Paroxysmal Nocturnal Hemoglobinuria and Other Hemolytic Disorders, Demonstrates Red Blood Cell Surface Targeting and Retention In a Model of Complement Alternative Pathway-Mediated Hemolysis

Amonafide L-Malate (AS1413) in Combination with Cytarabine Is Equally Effective in Older and Younger Patients with Secondary Acute Myeloid Leukemia (AML); Final Data From a Phase II Study

Suchergebnisse filtern